Company Profile
GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States.
The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors.
Its portfolio also includes GFH925, a small molecule selective inhibitor of KRAS G12C in a Phase II trial for the treatment of advanced NSCLC, and GFH009, a highly selective cyclin-dependent kinase (CDK) 9 inhibitor in a Phase II trial for the treatment of AML. It is also developing GFH276, a pan-RAS inhibitor in a Phase I trial for the treatment of solid tumors.
Its portfolio also includes GFS202A, a bispecific antibody in a Phase I trial for the treatment of cachexia, GFH312, a receptor-interacting serine/threonine-protein kinase (RIPK) 1 inhibitor in a Phase I clinical trial for the treatment of PAD with IC and PBC, GFS784, a pan-RAS antibody drug conjugate (ADC) candidate with an IND application for the treatment of solid tumors, and GFH946, an oral PROTAC product candidate with an IND application for the treatment of type 2 inflammation, as well as technical services.
It has collaboration agreements with Merck Healthcare KGaA for trials of combinational regimens, including cetuximab. Its portfolio also includes Verastem, Inc. to develop and commercialize GFH375, and SELLAS Life Sciences Group, Inc. to develop, manufacture, and commercialize GFH009. Incorporated in 2017, GenFleet Therapeutics (Shanghai) is headquartered in Shanghai, China.